SARS-CoV2 infection in those on Mepolizumab therapy

Coronavirus disease 2019 (COVID ‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1, continues to cause morbidity and mortality across the world. Expert recommendation is to continue biologic therapy unchanged in severe eosinophilic asthma 2,3 but concern has been expressed as eosinopenia may be a risk factor for worse disease outcomes 4. Here we report the outcomes of four patients from centres in the UK, Italy and North America with COVID-19, whilst receiving treatment with mepolizumab, an anti IL-5 monoclonal antibody, which reduces eosinophils to within the normal range 5.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research